Rec 15-2739 manufacturers
- Upidosin
-
- $39.00
-
2026-07-15
- CAS:152735-23-4
- Purity: 99.66%
- Supply Ability: 10g
|
| | Rec 15-2739 Basic information |
| Product Name: | Rec 15-2739 | | Synonyms: | 4H-1-Benzopyran-8-carboxamide, N-(3-(4-(2-methoxyphenyl)-1-piperazinyl)propyl)-3-methyl-4-oxo-2-phenyl-;Sb 216469-s;Unii-txg28R7G4y;Rec 15-2739;N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide;Recordati 15/2739;SB 216469;Upidosin, 10 mM in DMSO | | CAS: | 152735-23-4 | | MF: | C31H33N3O4 | | MW: | 511.61 | | EINECS: | | | Product Categories: | | | Mol File: | 152735-23-4.mol |  |
| | Rec 15-2739 Chemical Properties |
| Boiling point | 688.9±55.0 °C(Predicted) | | density | 1.208±0.06 g/cm3(Predicted) | | storage temp. | 4°C, protect from light | | pka | 14.40±0.40(Predicted) | | form | Solid | | color | White to off-white |
| | Rec 15-2739 Usage And Synthesis |
| Uses | Upidosin (Rec 15/2739) is an α-1 adrenoceptor (α-1 AR) antagonist. Upidosin shows moderate selectivity for the α-1A AR subtype. Upidosin shows uroselectivity in urethra and prostate with a Kb value of 2-3 nM higher than in ear artery and aorta with a Kb value of 20-100 nM. Upidosin inhibits [3H]prazosin binding to cloned human α-1A adrenergic receptor. Upidosin can be used for the research of urethral obstruction[1]. | | in vivo | Upidosin shows greater selectivity than any other α-1 AR antagonist terazosin and tamsulosin in the anesthetized dog[1].
Upidosin (1-300 μg/kg; i.v.) is a more potent antagonist of phenylephrine mediated increases in prostatic pressure with a pA2 value of 8.74 compared to blood pressure with a pA2 value of 7.51[3]. | | References | [1] Leonardi A, et al. Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther. 1997 Jun;281(3):1272-83. PMID:9190863
[2] Testa R, et al. Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery. J Pharmacol Exp Ther. 1996 Jun;277(3):1237-46. PMID:8667184
[3] Kenny BA, et al. Evaluation of the pharmacological selectivity profile of alpha 1 adrenoceptor antagonists at prostatic alpha 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol. 1996 Jun;118(4):871-8. DOI:10.1111/j.1476-5381.1996.tb15480.x |
| | Rec 15-2739 Preparation Products And Raw materials |
|